Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
ELVIRA D'ANDREA¹, Rishi Desai², Mengdong He³, Robert Glynn⁴, Hemin Lee², Michael Weinblatt², Daniel Solomon⁵ and Seoyoung Kim², ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
Abstract Number: L13 • ACR Convergence 2021
Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study
Cynthia Aranow¹, Cornelia Allaart², Zahir Amoura³, Ian N Bruce⁴, Patricia Cagnoli⁵, Richard Furie¹, Paul Peter Tak⁶, Murray Urowitz⁷, Ronald van Vollenhoven⁸, Kenneth L Clark⁶, Mark Daniels⁹, Norma Lynn Fox¹⁰, Yun Irene Gregan¹⁰, James Groark¹¹, Robert B Henderson⁹, Mary Oldham⁹, Don Shanahan⁹, Andre van Maurik⁹, David A Roth¹⁰ and YK Onno Teng², ¹Feinstein Institutes for Medical Research, Northwell Health, Great Neck, NY, ²Leiden University Medical Center, Leiden, Netherlands, ³Centre National de reference pour le Lupus, Service de Medecine Interne 2, Institut E3M, Hopital Pitié-Salpétrière, Paris, France, ⁴NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Trust and Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵University of Michigan Medical Center, Ann Arbor, MI, ⁶GlaxoSmithKline (At the time of the author's contribution to this study), Stevenage, United Kingdom, ⁷Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁸Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁹GlaxoSmithKline, Stevenage, United Kingdom, ¹⁰GlaxoSmithKline, Collegeville, PA, ¹¹GlaxoSmithKline (At the time of the author's contribution to this study), Collegeville, PA
Background/Purpose: Disease control remains an unmet need in SLE. The rationale for sequential BEL and RTX therapy in SLE was previously published.1 This study evaluated…
Abstract Number: L18 • ACR Convergence 2021
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
Satveer K Mahil¹, Katie Bechman², Antony Raharja¹, Clara Domingo-Vila³, David Baudry¹, Matt Brown², Andrew Cope², Tejus Dasandi¹, Hataf Khan⁴, Thomas Lechmere⁴, Michael Malim⁴, Freya Meynell¹, Emily Pollock³, Kamila Sychowska³, Jonathan Barker¹, Sam Norton⁵, James Galloway², Katie Doores⁴, Timothy Tree³ and Catherine Smith¹, ¹St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, ²Centre for Rheumatic Diseases, King's College London, London, ³Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, ⁴Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, ⁵Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
Abstract Number: 0100 • ACR Convergence 2021
Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey
Rebecca Hasseli¹, Bimba Franziska Hoyer², Hanns-Martin Lorenz³, Alexander Pfeil⁴, Jutta Richter⁵, Anne Regierer⁶, Tim Schmeiser⁷, Anja Strangfeld⁸, Reinhard Voll⁹, Andreas Krause¹⁰, Hendrik Schulze-Koops¹¹, Ulf Müller-Ladner¹² and Christof Specker¹³, ¹Justus-Liebig-University Giessen, Bad Nauheim, Germany, ²Universittsklinikum Schleswig-Holstein, Kiel, Germany, ³University Hospital Heidelberg Germany, Heidelberg, Germany, ⁴Friedrich Schiller University Jena, Jena, Germany, ⁵Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁶German Rheumatism Research Center, Berlin, Germany, ⁷Private Practice, Cologne, Germany, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁰Immanuel Hospital, Berlin, Germany, ¹¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹²JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ¹³Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany
Background/Purpose: Among patients with rheumatic and musculoskeletal diseases (RMDs) and their treating physicians, concerns prevail about the effectiveness and safety of vaccination against COVID-19, especially…
Abstract Number: 0587 • ACR Convergence 2021
DMARD Use in Medicare Patients with Rheumatoid Arthritis and Risk of Long-Term Opioid Use
Akhil Sood¹, Yong-Fang Kuo², Jordan Westra² and Mukaila Raji², ¹University of Texas Medical Branch, League City, TX, ²University of Texas Medical Branch, Galveston, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for opioid use. Disease-modifying antirheumatic drugs (DMARDs) have led to better control of disease activity.…
Abstract Number: 0834 • ACR Convergence 2021
Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry
Anthony Sebba¹, Clifton Bingham², Vivian Bykerk³, Stefano Fiore⁴, Kerri Ford⁵, Jud C Janak⁶, Dimitrios Pappas⁶, Taylor Blachley⁶, Swapna Dave⁶, Joel Kremer⁷, Miao Yu⁶ and Ernest Choy⁸, ¹Division of Rheumatology, University of South Florida, Tampa, FL, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, ⁸CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: RA patients who fail to achieve treatment targets with conventional synthetic DMARDs (csDMARDs) can be treated with biologics. Randomized controlled trials (RCTs) have shown…
Abstract Number: 1222 • ACR Convergence 2021
Drug Response Is Associated with Changes in Specific MicroRNAs in Patients with Rheumatoid Arthritis
Qiong Wu¹, Sheau-Chiann Chen¹, Fei Ye¹, Joseph Solus¹, S. Louis Bridges, Jr.², Jeffrey Curtis³, C. Michael Stein¹ and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Hospital for Special Surgery, New York, NY, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: MicroRNAs are markers and mediators of disease and drug response. Prior studies have proposed several miRNAs for prediction of drug response or monitoring drug…
Abstract Number: 1561 • ACR Convergence 2021
Prevalence of SARS-CoV2 Infection in Diseases Inflammatory Rheumatology in the Rheumatology Service of the Hospital Docente Padre Billini, Dominican Republic
Jennifer Santana Peralta de Heyaime, Teresandris Polanco Mora, Angelo Cornelio Vasquez, Yamilet Cruz, Edral Rodriguez, Tirso Valdez Lorie, Roberto Munoz and Rafael Alba Feriz, Hospital Docente Padre Billini, Santo Domingo, Dominican Republic
Background/Purpose: SARS-CoV-2 infection is caused by a new coronavirus. The World Health Organization (WHO) had information about the existence of this new virus on December…
Abstract Number: 1782 • ACR Convergence 2021
Disease Activity in Psoriatic Arthritis Patients with Enthesitis Across Different Therapies
Robert Chao¹, George Reed², Joel Kremer³ and Arthur Kavanaugh⁴, ¹Inova Health System, Fairfax, VA, ²University of Massachusetts, Worcester, MA, ³Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Evidence on the treatment of enthesitis, a common feature of psoriatic arthritis (PsA), is limited. This post-hoc, cross-sectional study examined if prevalent treatment choices…
Abstract Number: 0102 • ACR Convergence 2021
Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients
Anne Regierer¹, Rebecca Hasseli², Martin Schaefer¹, Bimba Franziska Hoyer³, Andreas Krause⁴, Hanns-Martin Lorenz⁵, Alexander Pfeil⁶, Jutta Richter⁷, Tim Schmeiser⁸, Anja Strangfeld⁹, Hendrik Schulze-Koops¹⁰, Reinhard Voll¹¹, Christof Specker¹² and Ulf Müller-Ladner¹³, ¹German Rheumatism Research Center, Berlin, Germany, ²Justus-Liebig-University Giessen, Bad Nauheim, Germany, ³Universittsklinikum Schleswig-Holstein, Kiel, Germany, ⁴Immanuel Hospital, Berlin, Germany, ⁵University Hospital Heidelberg Germany, Heidelberg, Germany, ⁶Friedrich Schiller University Jena, Jena, Germany, ⁷Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁸Private Practice, Cologne, Germany, ⁹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ¹⁰Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹¹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹²Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ¹³JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany
Background/Purpose: Due to the impressive efforts of the global scientific rheumatology community, increasing evidence about inflammatory rheumatic and musculoskeletal diseases (RMD) specific risk factors in…
Abstract Number: 0611 • ACR Convergence 2021
Association of Area Deprivation Index and Practice Patterns of Medicare Part D Rheumatologists
Shannon Tai¹, Ikechukwu Mbonu² and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, West Allis, WI, ³Medical College of Wisconsin, Brookfield, WI
Background/Purpose: Geographic disparities in the distribution and practice patterns of rheumatology providers may negatively impact patients with rheumatic diseases. The objective of this study was…
Abstract Number: 0837 • ACR Convergence 2021
Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial
Peter Nash¹, Arthur Kavanaugh², Maya Buch³, Bernard Combe⁴, Louis Bessette⁵, In-Ho Song⁶, Tim Shaw⁷, Yanna Song⁶, Jessica Suboticki⁶ and Roy Fleischmann⁸, ¹Griffith University, Brisbane, Australia, ²University of California San Diego, La Jolla, CA, ³University of Leeds, Leeds, United Kingdom, ⁴CHU Montpellier Montpellier University, Montpellier, France, ⁵Laval University, Québec City, QC, Canada, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment target for patients with active rheumatoid arthritis (RA) is sustained clinical remission (REM) or low disease activity (LDA).1,2 A greater proportion…
Abstract Number: 1225 • ACR Convergence 2021
Baseline Extracellular Matrix Biomarkers Predict Abatacept Treatment Response in MTX-Naive, ACPA+ Patients with Early RA
Paul Emery¹, Yoshiya Tanaka², Vivian Bykerk³, Clifton Bingham⁴, Tom WJ Huizinga⁵, Gustavo Citera⁶, Chun Wu⁷, Sarah Hu⁷, Peter Schafer⁷, Jinqi Liu⁷, Sean Connolly⁷, Robert Wong⁸ and Roy Fleischmann⁹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Basking Ridge, NJ, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Predictive biomarkers reflecting RA processes and treatment (tmt) efficacy are urgently needed to inform medical options. Markers of bone remodeling and extracellular matrix (ECM)…
Abstract Number: 1598 • ACR Convergence 2021
Trends in Medication Interruptions and Associations with Disease Flares During a Public Health Crisis: Longitudinal Data from Patients with Autoimmune Rheumatic Diseases During the COVID-19 Pandemic
Tiffany Dharia¹, Michael George², SHILPA VENKATACHALAM³, Shubhasree Banerjee², Joshua Baker², David Curtis⁴, Maria I. Danila⁵, Kelly Gavigan⁴, Peter Merkel², Dianne Shaw⁶, Jeffrey Curtis⁷ and William Nowell⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Vasculitis Foundation, Kansas City, MO, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The COVID-19 pandemic has had substantial impact on the care of patients with autoimmune rheumatic diseases (ARDs), resulting in frequent medication interruptions early in…
Abstract Number: 1810 • ACR Convergence 2021
Current Medication Practices and Preferences Among Patients with Psoriatic Arthritis (PsA)
Monica Schwartzman¹, Zafir Abutalib² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²The Hospital For Special Surgery, New York, NY
Background/Purpose: The advent of targeted synthetics and biologics has greatly broadened the options for effective treatment in PsA. Guidelines published in 2018 by the American…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].